Literature DB >> 16417600

Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations.

E-K Tan1.   

Abstract

In recent years, a number of potential new therapeutic indications of botulinum toxin injections have emerged, amongst which sialorrhea has attracted considerable attention. Based on open-label and controlled studies, botulinum toxin can be used to improve sialorrhea in patients with Parkinson's disease, parkinsonian syndromes, motor neuron disease and cerebral palsy. The toxin can be injected blindly based on anatomic landmarks of the salivary glands, or localization can be facilitated by use of ultrasound guidance. There are few reported adverse effects. However, many more carefully designed, controlled studies are still required to address the specific questions related to selection of patients, the optimal injection technique, the appropriate dose of botulinum toxin and its long-term effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417600     DOI: 10.1111/j.1468-1331.2006.01447.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  5 in total

1.  Impact of drooling in Parkinson's disease.

Authors:  Johanna G Kalf; Anne M Smit; Bastiaan R Bloem; Machiel J Zwarts; Marten Munneke
Journal:  J Neurol       Date:  2007-08-02       Impact factor: 4.849

2.  Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis.

Authors:  João Costa; Maria Luz Rocha; Joaquim Ferreira; Teresinha Evangelista; Miguel Coelho; Mamede de Carvalho
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

3.  Onabotulinumtoxin A Treatment of Drooling in Children with Cerebral Palsy: A Prospective, Longitudinal Open-Label Study.

Authors:  Eigild Møller; Søren Anker Pedersen; Pablo Gustavo Vinicoff; Allan Bardow; Joan Lykkeaa; Pia Svendsen; Merete Bakke
Journal:  Toxins (Basel)       Date:  2015-06-30       Impact factor: 4.546

4.  Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience.

Authors:  Javier Martínez-Poles; Velina Nedkova-Hristova; José Bernardo Escribano-Paredes; Sebastián García-Madrona; Elena Natera-Villalba; Carlos Estévez-Fraga; José Luis López-Sendón Moreno; Icíar Avilés-Olmos; Gema Sánchez Díaz; Juan Carlos Martínez Castrillo; Araceli Alonso-Canovas
Journal:  Toxins (Basel)       Date:  2018-05-28       Impact factor: 4.546

5.  Neurologic uses of botulinum neurotoxin type A.

Authors:  John P Ney; Kevin R Joseph
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.